Abstract
Systemic mastocytosis with associated clonal hematological non-mast cell lineage disease (SM-AHNMD) is a unique subtype of mast cell neoplasm. In most SMAHNMD cases, it is the myeloid malignancy that accompanies systemic mastocytosis (SM), and cases of associated chronic lymphoproliferative neoplasm or plasma cell dyscrasia are relatively infrequent. Concurrent clinical presentation of SM with aggressive refractory plasma cell myeloma is a very rare entity. We documented CD30 expression on the neoplastic mast cells in the bone marrow biopsy specimen from a patient. It has been reported that neoplastic mast cells can express CD30 ligand, which enhances their growth and is associated with aggressive SM. This finding could have therapeutic implications for the treatment of SM with anti-CD30 monoclonal antibody.
Original language | English (US) |
---|---|
Pages (from-to) | 459-462 |
Number of pages | 4 |
Journal | Clinical Lymphoma, Myeloma and Leukemia |
Volume | 12 |
Issue number | 6 |
DOIs | |
State | Published - Dec 2012 |
Keywords
- Plasma cell neoplasms
- SM-AHNMD
- Systemic mastocytosis
ASJC Scopus subject areas
- Hematology
- Oncology
- Cancer Research